G42 Healthcare

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 3
GlucokinaseSmall molecule
Type 1 Diabetes

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
April 2027 (1)
cadisegliatinPhase 3Diabetes Mellitus, Type 1
Est. primary completion 2027-04 · NCT06334133 · CT.gov ↗
What to watch
June 2027 (1)
cadisegliatinPhase 2Type 1 Diabetes (T1D)
Est. primary completion 2027-06 · NCT07616206 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.